ED
CBAY

Exane Derivatives’s Cymabay Therapeutics CBAY Stock Holding History

Exane Derivatives’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36,133
Closed -$132K – 1103
2021
Q3 		$132K Buy
36,133
+1,919
+6% +$7.56K 0.03% 489
2021
Q2 		$146K Buy
+34,214
New +$152K 0.03% 486

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Exane Derivatives's CBAY Position: Q4 2021 in Review

Exane Derivatives sold out of Cymabay Therapeutics (CBAY) in Q4 2021, closing a stake of 36,133 shares — an estimated $132K sold.

Exane Derivatives first reported a position in CBAY in Q2 2021 and held it in 2 quarters. The position peaked at $146K in Q2 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2021.

  • Exane Derivatives reported no remaining Cymabay Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Exane Derivatives sold 36,133 Cymabay Therapeutics shares in Q4 2021, an estimated $132K.
  • Exane Derivatives first reported a position in Cymabay Therapeutics in Q2 2021 and held it in 2 quarters.
  • Exane Derivatives's Cymabay Therapeutics position peaked at $146K in Q2 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.